Rubella eradication

Vaccine

Volumn 19, Issue 25-26, 2001, Pages 3311-3319

  Plotkin, Stanley A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE; RUBELLA VACCINE;

CONGENITAL RUBELLA SYNDROME; EPIDEMIC; ERADICATION THERAPY; INFECTION CONTROL; MEASLES; PRIORITY JOURNAL; REVIEW; RUBELLA; RUBELLA VIRUS; VIRUS VIRULENCE;

DISEASE OUTBREAKS; ENVIRONMENTAL MONITORING; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RUBELLA; RUBELLA VACCINE; SYNDROME; UNITED STATES;

EID: 0035858126     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00073-1     Document Type: Review

References (66)

1. Congenital cataract following German measles in the mother
2. Rubella vaccine
3. Historical review and summary of meeting objectives
4. Congenital rubella syndrome in late infancy
5. Rubella
6. Consequences of confirmed maternal rubella at successive stages of pregnancy
7. Teratogen update: The congenital rubella syndrome
8. Rubella infection during pregnancy in the 1985-1986 epidemic
9. Modelling rubella in Europe
10. Rubella infection: The Indian scene
11. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: Burden of disease from CRS
12. Salivary diagnosis of rubella: As study of notified cases in the United Kingdom, 1991-4
13. Febrile rash illness surveillance as part of measles control/elimination
14. Preparing for elimination of congenital rubella syndrome (CRS): Summary of a workshop on CRS elimination in the United States
15. Clinical-epidemiologic assessment of patterns of birth defects associated with human teratogens: Application to diabetic embropathy
16. Attenuation of RA 27/3 rubella virus in WI-38 human diploid cells
17. Clinical and laboratory studies of live attenuated RA 27/3 and HPV-77DE rubella virus vaccines
18. Viremia, virus excretion and antibody responses after challenge to volunteers with low levels of antibody to rubella virus
19. Outcome of pregnancy after maternal reinfection with rubella
20. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated your adults
21. History of RA 27/3 rubella vaccine
22. Measles: Reassessment of the current immunization policy
23. Simultaneous control of measles and rubella by multidose vaccination schedules
24. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins
25. A randomised single blind trial of a combined mumps-measles-rubella vaccine to evaluate serological response and reactions in the UK population
26. Vaccination against rubella of susceptible schoolgirls in reading
27. A controlled comparison of joint reactions among women receiving one of two rubella vaccines
28. Postpartum rubella immunization: Association with development of prolonged arthritis, neurological sequelae and chronic rubella viremia
29. Absence of an association between rubella vaccination and arthritis in underimmune postpartum women
30. Risk of chronic arthropathy among women after rubella vaccination
31. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women
32. Fetal risk associated with rubella vaccine: An update
33. Rubella antibody titers in vaccinated and nonvaccinated women and results of vaccination during pregnancy
34. Rubella vaccination and pregnancy: Preliminary report of a national survey
35. Rubella vaccination during pregnancy - United States 1971-1986
36. Rubella vaccination in the United States: A 10 year review
37. Measles prevention
38. Congenital rubella syndrome in the United States, 1970-1985. On the verge of elimination
39. Changing epidemiology of congenital rubella syndrome in the United States
40. A large rubella outbreak with spread from the workplace to the community
41. Selective immunization: Protection of the individual
42. Measles, mumps and rubella: The need for a change in immunization policy
43. Rubella in the United Kingdom
44. Twenty years' experience of rubella vaccination in Sweden: 10 Years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination
45. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program
46. Rubella immunity and morbidity: Impact of different vaccination programs in Finland 1979-1992
47. Épidémiologie de la rubéole en France, 20 ans après la mise en place de la vaccination
48. Opening statement
49. India experience with CRS surveillance
50. Unseen blindness, unheard deafness, and unrecorded death and disability: Congenital rubella in Kumasi, Ghana
51. Prevalence of rubella antibodies on the African continent
52. Prevalence of rubella-IgG antibody in women of childbearing age in Lagos, Nigeria
53. Modelling the incidence of congenital rubella syndrome in developing countries
54. Global production capacity for measles, MR, and MMR vaccines
55. Measles, mumps, and rubella immunization at nine months in a developing country
56. Vaccination against rubella and measles: Quantitative investigations of different policies
57. Increase in congenital rubella occurrence after immunisation in Greece: Retrospective survey and systematic review
58. Incidence of congenital rubella in Greece has decreased
59. Sero-epidemiology of rubella in the urban population of Addis Ababa, Ethiopia
60. Assessing the efficacy of a mixed vaccination strategy against rubella in Sao Paulo, Brazil
61. Rational use of rubella vaccine for prevention of congenital rubella syndrome in the Americas